Home/Pipeline/PEPR112

PEPR112

Oncology

Lead OptimizationPreclinical

Key Facts

Indication

Oncology

Phase

Lead Optimization

Status

Preclinical

Company

Peptris Technologies Private

About Peptris Technologies Private

AI-driven drug discovery company using proprietary generative AI to design novel molecules and repurpose drugs for oncology, inflammation, and rare diseases.

View full company profile

Therapeutic Areas

Oncology Inflammation Rare Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active